Strain-Engineered Biosimilars for Competitive, Scalable Manufacture
Phenotypeca develops proprietary biosimilars by using our QTL technology platform to create optimised manufacturing strains. These strains are designed not only to meet the bioequivalence requirements of the reference product but also to deliver superior technical and commercial capabilities.
What Makes Our Biosimilars Different
- Strain Ownership – We create an optimised production strain, which is patent-protected for each biosimilar
- Manufacturing Advantage – Higher yields, greater reproducibility, and lower cost per unit
- Regulatory Ready – Consistent batch quality matching reference standard using a well-established, regulatory-friendly expression host
Licensing-Ready Products
- Semaglutide – A semi-recombinant strain delivering cost-effective production of this GLP-1 analogue
- Recombinant Albumin – High-yield strain suitable for plasma expansion
- Sargramostim – Manufacturing strain optimised to secrete this GM-CSF analogue for acute radiation syndrome.
Download: Semaglutide PDF • Sargramostim PDF • Albumin PDF
Contact us for licensing discussions
